Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Summary
Lilly’s GLP-1 boom was an 18-year compounding bet: the episode opens by noting that Lilly’s market capitalization rose about 860% since Ricks became CEO and its stock a little more than 1,000%; Ricks reported tirzepatide at $8.1 billion of Q2 revenue after surpassing Keytruda, while the host separately cited 80% growth. The decisive 2016 signal was a trial stopped because healthy male volunteers in Singapore were “losing too much weight too quickly”; Ricks now estimates roughly 20 million people use prescription GLP-1s globally.
Access is now the constraint and fault line: Lilly cut its direct out-of-pocket price from $1,000 to $499, guided investors to single-digit category deflation over time, and says an oral drug is coming next year. Ricks committed to lower prices but warned that if the price fell to $100, it could “snuff out” next-generation R&D; his larger goal is insurance reimbursement, noting that antihypertensives and even surgeries that do not work are covered, while poor coverage helps drive demand for compounded and gray-market alternatives.
At Lilly, Ricks favors reinvesting rather than harvesting the windfall because “everything we make goes to zero” when patents expire, including Mounjaro in 2030-something. Lilly spends 25% of sales on R&D—$14.2 billion this year—and is constructing six U.S. plants, with four more announcements planned within six months, supporting 20,000 construction and ultimately 5,000-6,000 manufacturing jobs.
Biotech distress is making funding scarce while Lilly continues buying external innovation: annual new checks have fallen from roughly $20 billion to $5 billion, and half of publicly traded biotech trades at or below cash. Lilly is doing mostly small deals about every two weeks; Ricks blamed AI’s capital crowd-out, excessive biotech IPOs and China’s subsidized “swarm model,” with Chinese teams using disclosed chemical structures and sometimes AI to design around patent scope.
The largest medical optionality may sit beyond weight loss. Ricks said smoking cessation became obvious as GLP-1 studies scaled; the host cited gambling and online shopping, while Ricks also mentioned less drinking among broader benefits. Mounjaro reduced progression from prediabetes to diabetes by 93%, and Lilly is starting bipolar, major-depression and addictive/hedonic-pathway studies using a GLP-1 designed for “a little less weight loss but a little more brain activity”; if successful, Ricks said that drug could arrive in three or four years.
Ricks’s healthcare critique was unusually candid: he favors less direct-to-consumer drug advertising, says PBMs may have reached “the end of that S-curve,” and supports scrutiny of NIH grant allocation while saying the effects of proposed cuts are not obvious. He aligned with Bobby Kennedy’s food-system reform focus but worried about restricting vaccine access during scientific review, preserving a distinction between healthy skepticism and policy imposed before evidence is settled.
Deep dive
1. The “overnight” GLP-1 success took 18 years
Ricks’s history begins with Lilly’s twice-daily diabetes injection in 2006. Its 2007 annual report already quoted a patient saying, “My diabetes is under control and I’m losing a little bit of weight,” while successive versions improved convenience and dosing.
In 2014, four Lilly scientists combined GLP-1 with another appetite-suppressing peptide in one molecule. By 2016, a Singapore study stopped because healthy male volunteers were “losing too much weight too quickly”—“They were basically not eating.”
Lilly then treated scale as an execution problem: factories, supply chains and a massive clinical program now exceeding 100 studies. Tirzepatide produced $8.1 billion in Q2 revenue and, Ricks said, surpassed Keytruda; the host also cited 80% growth, without specifying what the figure measured. Ricks estimates about 20 million prescription GLP-1 users worldwide.
2. Price will fall, but Ricks says reimbursement matters more
The opening says Lilly’s experimental pill appears to work as well as the injected drug; Ricks said the oral medicine is coming next year.
The host described his own “food noise” as “constantly screaming.” Treatment pushed his BMI below 30; he later cycled off and returned at an extremely low dose, now paid out of pocket.
The host’s pushback was a moral challenge to halve prices when profits and health consequences are both enormous. Ricks said Lilly had moved its direct price from $1,000 to $499, would push lower with oral medicines, and told Wall Street to expect single-digit deflation over time—potentially “or more.”
Ricks’s warning was conditional: if the price were cut to $100, “there will be no more new medicines in this category.” He said the main goal for orals is reimbursement—if plans cover chronic antihypertensives and even surgeries that do not work, he argued, excluding anti-obesity drugs “makes no sense.”
3. Lilly is spending the windfall before the patent cliff
Ricks rejects treating the franchise as permanent: “Everything we make goes to zero because of the patent system.” In his example, Mounjaro will go to zero in 2030-something. Organic R&D comes first—25% of sales, or $14.2 billion this year—with roughly 4,200 Ph.D. scientists, a scientific workforce he compared with MIT and Harvard combined.
Asked how he encourages moonshots, Ricks said the bigger problem is not a shortage of big ideas but the lack of a path to advance them inside a large company rather than leaving to raise venture capital.
Supply comes second. Lilly is constructing six U.S. plants and expects to announce four more within six months, creating 20,000 construction jobs and eventually 5,000-6,000 manufacturing jobs. At scale, Ricks expects Lilly to become a net exporter; he said it would be hard for others to follow unless a Chinese state-owned enterprise enters the business.
4. Biotech funding has cratered while Lilly keeps buying external innovation
Biotech funding is “in a dumpster fire”: annual new checks have fallen from roughly $20 billion to $5 billion, and half of publicly traded biotech trades at or below cash. Ricks cited competition from faster-return AI ventures and too many prior biotech IPOs.
Lilly is buying external innovation where it fits, doing a deal about every two weeks, most of them smallish, and acquiring a gene-therapy company in June.
Ricks’s China mechanism starts with the U.S. shift to first-to-file patents in 2011; he said he thought the relevant law was the America Invents Act. The change encourages companies to file quickly, exposing inventions to the world. Chinese teams then “work backwards,” sometimes with AI, from chemical structures to find similar structures outside the patent scope—a derivative model that hurts biotech valuations.
5. The platform is moving from metabolism into compulsion and the brain
Ricks has not taken a GLP-1 himself—“yet”—but thinks that, as safety is proven, sufficiently low doses may eventually be reasonable for many people over 60, or even over 58, and “may help you live longer.”
Ricks said smoking cessation became obvious when studies scaled; the host added gambling and online shopping, while Ricks had cited less drinking and lower inflammation among broader benefits. Lilly is starting studies in bipolar disorder and major depressive disorder, along with addictive and hedonic pathways, using another GLP-1 offering “a little less weight loss but a little more brain activity.” His timeline remained conditional: three or four years “if it works.”
Lilly showed Mounjaro reduced progression from prediabetes to diabetes by 93%. Ricks guessed an upcoming Novo dementia-risk study “probably won’t be positive,” but said it may move in the right direction.
His broader call is that the next surprise category will probably be brain disease, which he said represents 40% of human suffering globally and remains poorly treated.
6. Ricks thinks healthcare’s incentives need rewiring
Ricks said he thinks the U.S. is the least healthy major country metabolically, suggesting processed food and chemicals are probably a major reason. He said anti-fat, high-carbohydrate diets contributed to a large part of the obesity curve and favored making quality food cheaper and more accessible. He aligned with Bobby Kennedy’s food-reform focus but worried about restricting vaccine access while scientific questions are being examined.
Challenged over drug advertising and media capture, Ricks favored a system with much less advertising. He described the competitive ad cycle as a little like “mutually assured destruction,” after the host called it a prisoner’s dilemma, and blamed awkward TV disclosures partly on a 1992 FDA regulation written for magazine print advertisements.
On the NIH’s little-over-$40 billion budget, Ricks’s answer was deliberately uncertain: government enabled landmark work such as mapping the human genome, but dispersed extramural grants may be either productive venture-style experimentation or strategy-free diffusion. He also worried about a backscratching dynamic in which people making grants are themselves grant recipients. Universities have produced much good, he said, but NIH should not exclude other applicants.
PBMs once solved claims adjudication and pooled purchasing, Ricks said, but the 1993-era IT problem is no longer difficult. Lilly itself is moving toward a transparent or “light” PBM because service is better; consolidation has made “every action” serve the intermediary rather than the customer.